BHCM
ARQT icon

Boulder Hill Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Boulder Hill Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,900
Closed -$247K – 135
2022
Q3 		$247K Buy
+12,900
New +$292K 0.19% 119

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boulder Hill Capital Management's ARQT Position: Q4 2022 in Review

Boulder Hill Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2022, closing a stake of 12,900 shares — an estimated $247K sold.

Boulder Hill Capital Management first reported a position in ARQT in Q3 2022 and held it in 1 quarter. The position peaked at $247K in Q3 2022. 141 funds tracked by Wall St. Rank hold ARQT as of Q4 2022.

  • Boulder Hill Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 12,900 Arcutis Biotherapeutics shares in Q4 2022, an estimated $247K.
  • Boulder Hill Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Arcutis Biotherapeutics position peaked at $247K in Q3 2022.
  • 141 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2022.

Based on Boulder Hill Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.